Premium
CD34 + cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome
Author(s) -
Heinrichs Stefan,
Berman Jason N.,
Ortiz Taylor M.,
Kornblau Steven M.,
Neuberg Donna S.,
Estey Elihu H.,
Thomas Look A.
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2005.05555.x
Subject(s) - cd34 , progenitor cell , bone marrow , myelodysplastic syndromes , cancer research , myeloid , medicine , haematopoiesis , international prognostic scoring system , stem cell , pathogenesis , cell , oncology , immunology , biology , genetics
Summary Overexpression of HOXA9 is linked to the molecular pathogenesis of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), conferring a poor prognosis. HOXA9 expression levels were analysed in the diagnostic bone marrow (BM) samples of 13 MDS patients. HOXA9 was expressed by CD34 + BM cells at median levels 3·1‐fold higher than in CD34 − cells from the same patient and at median levels 4·3‐fold higher than in CD34 + cells from healthy donors. These results indicate that CD34 + cell selection is required to accurately assess the expression levels of HOXA9 and related genes in the multipotential malignant progenitor cells of MDS patients.